ASX Announcement 27 October 2026 OncoSil™ Study Reports 100% Local Disease Control and Promising Surgical Outcomes in Locally Advanced Pancreatic Cancer Key highlights • Peer-reviewed clinical study published in the international oncology journal Cancers, reporting early outcomes in 17 patients...
Peer-Reviewed Study Reports 100% Disease Control
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Change of Director's Interest Notice
- Notification of cessation of securities - OSL
- Updated OSPREY Overall Survival Data Presented at EAMN
- Notice of Annual General Meeting/Proxy Form
- Application for quotation of securities - OSL
Later from OncoSil Medical
- Annual Report (Typeset)
- Quarterly Activities/Appendix 4C Cash Flow Report
- Regulatory Application Filed for Australian Manufacturing
